CAR T-cell Therapy Market Size, Share & Trends Analysis Report By Product (Abecma, Breyanzi, Carvykti, Kymriah), By Disease Indication (Lymphoma, Leukemia, Multiple Myeloma), By End Use, By Region, And Segment Forecasts, 2026 - 2033

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Product Segment
    • 1.1.1.2. Disease Indication Segment
    • 1.1.1.3. End Use Segment
• 1.2. Regional Scope
• 1.3. Estimates and Forecast Timeline
• 1.4. Objective
  • 1.4.1. Objective 1
  • 1.4.2. Objective2
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information or Data Analysis:
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
• 1.10. List of Secondary Sources
• 1.11. List of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising cancer burden
    • 3.2.1.2. Personalized treatment advantage
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Regulatory complexity
• 3.3. Industry Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis

Chapter 4. Product Business Analysis

• 4.1. Product Segment Dashboard
• 4.2. CAR T-cell Therapy Market: Product Movement Analysis
• 4.3. Abecma (idecabtagene vicleucel)
  • 4.3.1. Abecma (idecabtagene vicleucel) market, 2021 - 2033 (USD Million)
• 4.4. Breyanzi (lisocabtagene maraleucel)
  • 4.4.1. Breyanzi (lisocabtagene maraleucel) market, 2021 - 2033 (USD Million)
• 4.5. Carvykti (ciltacabtagene autoleucel)
  • 4.5.1. Carvykti (ciltacabtagene autoleucel) market, 2021 - 2033 (USD Million)
• 4.6. Kymriah (tisagenlecleucel)
  • 4.6.1. Kymriah (tisagenlecleucel) market, 2021 - 2033 (USD Million)
• 4.7. Tecartus (brexucabtagene autoleucel)
  • 4.7.1. Tecartus (brexucabtagene autoleucel) market, 2021 - 2033 (USD Million)
• 4.8. Yescarta (axicabtagene ciloleucel)
  • 4.8.1. Yescarta (axicabtagene ciloleucel) market, 2021 - 2033 (USD Million)
• 4.9. Others
  • 4.9.1. Others market, 2021 - 2033 (USD Million)

Chapter 5. Disease Indication Business Analysis

• 5.1. Disease Indication Segment Dashboard
• 5.2. CAR T-cell Therapy Market: Disease Indication Movement Analysis
• 5.3. Leukemia
  • 5.3.1. Leukemia market, 2021 - 2033 (USD Million)
• 5.4. Lymphoma
  • 5.4.1. Lymphoma market, 2021 - 2033 (USD Million)
• 5.5. Multiple Myeloma
  • 5.5.1. Multiple myeloma market, 2021 - 2033 (USD Million)
• 5.6. Others
  • 5.6.1. Others market, 2021 - 2033 (USD Million)

Chapter 6. End Use Business Analysis

• 6.1. End Use Segment Dashboard
• 6.2. CAR T-cell Therapy Market: End Use Movement Analysis
• 6.3. Hospitals
  • 6.3.1. Hospitals market, 2021 - 2033 (USD Million)
• 6.4. Cancer treatment centers
  • 6.4.1. Cancer treatment centers market, 2021 - 2033 (USD Million)

Chapter 7. Regional Business Analysis

• 7.1. CAR T-cell Therapy Market Share By Region, 2025 & 2033
• 7.2. North America
  • 7.2.1. North America CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
  • 7.2.2. U.S.
    • 7.2.2.1. Key Country Dynamics
    • 7.2.2.2. Competitive Scenario
    • 7.2.2.3. Regulatory Framework
    • 7.2.2.4. U.S. CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
  • 7.2.3. Canada
    • 7.2.3.1. Key Country Dynamics
    • 7.2.3.2. Competitive Scenario
    • 7.2.3.3. Regulatory Framework
    • 7.2.3.4. Canada CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
• 7.3. Europe
  • 7.3.1. Europe CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
  • 7.3.2. UK
    • 7.3.2.1. Key Country Dynamics
    • 7.3.2.2. Competitive Scenario
    • 7.3.2.3. Regulatory Framework
    • 7.3.2.4. UK CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
  • 7.3.3. Germany
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Competitive Scenario
    • 7.3.3.3. Regulatory Framework
    • 7.3.3.4. Germany CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
• 7.4. Asia Pacific
  • 7.4.1. Asia Pacific CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
  • 7.4.2. Japan
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. Japan CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
  • 7.4.3. China
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. China CAR T-cell Therapy Market, 2021 - 2033 (USD Million)
• 7.5. Rest of World
  • 7.5.1. Rest of World CAR T-cell Therapy Market, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
• 8.2. Strategy Mapping
• 8.3. Company Position Analysis, 2025
• 8.4. Company Profiles/Listing
  • 8.4.1. Bristol-Myers Squibb Company
    • 8.4.1.1. Overview
    • 8.4.1.2. Financial Performance
    • 8.4.1.3. Product Benchmarking
    • 8.4.1.4. Strategic Initiatives
  • 8.4.2. Novartis AG
    • 8.4.2.1. Overview
    • 8.4.2.2. Financial Performance
    • 8.4.2.3. Product Benchmarking
    • 8.4.2.4. Strategic Initiatives
  • 8.4.3. Gilead Sciences, Inc.
    • 8.4.3.1. Overview
    • 8.4.3.2. Financial Performance
    • 8.4.3.3. Product Benchmarking
    • 8.4.3.4. Strategic Initiatives
  • 8.4.4. Johnson & Johnson Services, Inc.
    • 8.4.4.1. Overview
    • 8.4.4.2. Financial Performance
    • 8.4.4.3. Product Benchmarking
    • 8.4.4.4. Strategic Initiatives
  • 8.4.5. JW Therapeutics (Shanghai) Co., Ltd.
    • 8.4.5.1. Overview
    • 8.4.5.2. Financial Performance
    • 8.4.5.3. Product Benchmarking
    • 8.4.5.4. Strategic Initiatives
  • 8.4.6. bluebird bio, Inc.
    • 8.4.6.1. Overview
    • 8.4.6.2. Financial Performance
    • 8.4.6.3. Product Benchmarking
    • 8.4.6.4. Strategic Initiatives
  • 8.4.7. Merck & Co., Inc.
    • 8.4.7.1. Overview
    • 8.4.7.2. Financial Performance
    • 8.4.7.3. Product Benchmarking
    • 8.4.7.4. Strategic Initiatives
  • 8.4.8. Sangamo Therapeutics
    • 8.4.8.1. Overview
    • 8.4.8.2. Financial Performance
    • 8.4.8.3. Product Benchmarking
    • 8.4.8.4. Strategic Initiatives
  • 8.4.9. Sorrento Therapeutics, Inc.
    • 8.4.9.1. Overview
    • 8.4.9.2. Financial Performance
    • 8.4.9.3. Product Benchmarking
    • 8.4.9.4. Strategic Initiatives
  • 8.4.10. GSK plc.
    • 8.4.10.1. Overview
    • 8.4.10.2. Financial Performance
    • 8.4.10.3. Product Benchmarking
    • 8.4.10.4. Strategic Initiatives

List of Tables

• Table 1. Global CAR T-cell therapy market, by region, 2021 - 2033 (USD Million)
• Table 2. Global CAR T-cell therapy market, by product, 2021 - 2033 (USD Million)
• Table 3. Global CAR T-cell therapy market, by disease indication, 2021 - 2033 (USD Million)
• Table 4. Global CAR T-cell therapy market, by end use, 2021 - 2033 (USD Million)
• Table 5. North America CAR T-cell therapy market, by country, 2021 - 2033 (USD Million)
• Table 6. North America CAR T-cell therapy market, by product, 2021 - 2033 (USD Million)
• Table 7. North America CAR T-cell therapy market, by disease indication, 2021 - 2033 (USD Million)
• Table 8. North America CAR T-cell therapy market, by end use, 2021 - 2033 (USD Million)
• Table 9. U.S. CAR T-cell therapy market, by product, 2021 - 2033 (USD Million)
• Table 10. U.S. CAR T-cell therapy market, by disease indication, 2021 - 2033 (USD Million)
• Table 11. U.S. CAR T-cell therapy market, by end use, 2021 - 2033 (USD Million)
• Table 12. Canada CAR T-cell therapy market, by product, 2021 - 2033 (USD Million)
• Table 13. Canada CAR T-cell therapy market, by disease indication, 2021 - 2033 (USD Million)
• Table 14. Canada CAR T-cell therapy market, by end use, 2021 - 2033 (USD Million)
• Table 15. Europe CAR T-cell therapy market, by country, 2021 - 2033 (USD Million)
• Table 16. Europe CAR T-cell therapy market, by product, 2021 - 2033 (USD Million)
• Table 17. Europe CAR T-cell therapy market, by disease indication, 2021 - 2033 (USD Million)
• Table 18. Europe CAR T-cell therapy market, by end use, 2021 - 2033 (USD Million)
• Table 19. UK CAR T-cell therapy market, by product, 2021 - 2033 (USD Million)
• Table 20. UK CAR T-cell therapy market, by disease indication, 2021 - 2033 (USD Million)
• Table 21. UK CAR T-cell therapy market, by end use, 2021 - 2033 (USD Million)
• Table 22. Germany CAR T-cell therapy market, by product, 2021 - 2033 (USD Million)
• Table 23. Germany CAR T-cell therapy market, by disease indication, 2021 - 2033 (USD Million)
• Table 24. Germany CAR T-cell therapy market, by end use, 2021 - 2033 (USD Million)
• Table 25. Asia Pacific CAR T-cell therapy market, by country, 2021 - 2033 (USD Million)
• Table 26. Asia Pacific CAR T-cell therapy market, by product, 2021 - 2033 (USD Million)
• Table 27. Asia Pacific CAR T-cell therapy market, by disease indication, 2021 - 2033 (USD Million)
• Table 28. Asia Pacific CAR T-cell therapy market, by end use, 2021 - 2033 (USD Million)
• Table 29. Japan CAR T-cell therapy market, by product, 2021 - 2033 (USD Million)
• Table 30. Japan CAR T-cell therapy market, by disease indication, 2021 - 2033 (USD Million)
• Table 31. Japan CAR T-cell therapy market, by end use, 2021 - 2033 (USD Million)
• Table 32. China CAR T-cell therapy market, by product, 2021 - 2033 (USD Million)
• Table 33. China CAR T-cell therapy market, by disease indication, 2021 - 2033 (USD Million)
• Table 34. China CAR T-cell therapy market, by end use, 2021 - 2033 (USD Million)
• Table 35. Rest or World CAR T-cell therapy market, by country, 2021 - 2033 (USD Million)
• Table 36. Rest of World CAR T-cell therapy market, by product, 2021 - 2033 (USD Million)
• Table 37. Rest of World CAR T-cell therapy market, by disease indication, 2021 - 2033 (USD Million)
• Table 38. Rest of World CAR T-cell therapy market, by end use, 2021 - 2033 (USD Million)

List of Figures

• Fig. 1 CAR T-cell therapy market segmentation
• Fig. 2 Data analysis models
• Fig. 3 Market formulation and validation
• Fig. 4 Data validating & publishing
• Fig. 5 Market research process
• Fig. 6 Information procurement
• Fig. 7 Primary research
• Fig. 8 Value-chain-based sizing & forecasting
• Fig. 9 QFD modelling for market share assessment
• Fig. 10 Market formulation & validation
• Fig. 11 Commodity flow analysis
• Fig. 12 Market outlook
• Fig. 13 Segment snapshot
• Fig. 14 Competitive landscape snapshot
• Fig. 15 Market trends & outlook
• Fig. 16 PESTEL analysis
• Fig. 17 Porter's five forces analysis
• Fig. 18 CAR T-cell therapy market: Product outlook & key takeaways
• Fig. 19 CAR T-cell therapy market: Product movement analysis
• Fig. 20 Global abecma (idecabtagene vicleucel) market, 2021 - 2033 (USD Million)
• Fig. 21 Global breyanzi (lisocabtagene maraleucel) market, 2021 - 2033 (USD Million)
• Fig. 22 Global carvykti (ciltacabtagene autoleucel) market, 2021 - 2033 (USD Million)
• Fig. 23 Global kymriah (tisagenlecleucel) market, 2021 - 2033 (USD Million)
• Fig. 24 Global tecartus (brexucabtagene autoleucel) market, 2021 - 2033 (USD Million)
• Fig. 25 Global yescarta (axicabtagene ciloleucel) market, 2021 - 2033 (USD Million)
• Fig. 26 Global others market, 2021 - 2033 (USD Million)
• Fig. 27 CAR T-cell therapy market: Disease Indication outlook key takeaways
• Fig. 28 CAR T-cell therapy market: Disease Indication movement analysis
• Fig. 29 Global leukemia market, 2021 - 2033 (USD Million)
• Fig. 30 Global lymphoma market, 2021 - 2033 (USD Million)
• Fig. 31 Global multiple myeloma market, 2021 - 2033 (USD Million)
• Fig. 32 Global others market, 2021 - 2033 (USD Million)
• Fig. 33 CAR T-cell therapy market: End Use outlook key takeaways
• Fig. 34 CAR T-cell therapy market: End Use movement analysis
• Fig. 35 Global hospitals market, 2021 - 2033 (USD Million)
• Fig. 36 Global cancer treatment centers market, 2021 - 2033 (USD Million)
• Fig. 37 Regional outlook
• Fig. 38 Regional marketplace: Key takeaways
• Fig. 39 North America CAR T-cell therapy market estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 40 Key country dynamics
• Fig. 41 US CAR T-cell therapy market estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 42 Key country dynamics
• Fig. 43 Canada CAR T-cell therapy market estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 44 Europe CAR T-cell therapy market estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 45 Key country dynamics
• Fig. 46 Germany CAR T-cell therapy market estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 47 Key country dynamics
• Fig. 48 UK CAR T-cell therapy market estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 49 Asia Pacific CAR T-cell therapy market estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 50 Key country dynamics
• Fig. 51 Japan CAR T-cell therapy market estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 52 Key country dynamics
• Fig. 53 China CAR T-cell therapy market estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 54 Rest of World CAR T-cell therapy market estimates and forecasts, 2021 - 2033 (USD Million)